Rigel Pharmaceuticals (RIGL) Stock Forecast, Price Target & Predictions
RIGL Stock Forecast
Rigel Pharmaceuticals stock forecast is as follows: an average price target of $1.50 (represents a -88.74% downside from RIGL’s last price of $13.32) and a rating consensus of 'Buy', based on 5 wall street analysts offering a 1-year stock forecast.
RIGL Price Target
The average price target for Rigel Pharmaceuticals (RIGL) is $1.50 based on 1-year price targets from 5 Wall Street analysts in the past 3 months, with a price target range of $2.00 to $1.00. This represents a potential -88.74% downside from RIGL's last price of $13.32.
RIGL Analyst Ratings
According to 5 Wall Street analysts, Rigel Pharmaceuticals's rating consensus is 'Buy'. The analyst rating breakdown for RIGL stock is 0 'Strong Buy' (0.00%), 4 'Buy' (80.00%), 1 'Hold' (20.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Rigel Pharmaceuticals Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Aug 17, 2022 | - | Piper Sandler | $2.00 | $1.56 | 28.21% | -84.98% |
| Jun 08, 2022 | Eun Yang | Jefferies | $1.00 | $0.71 | 41.04% | -92.49% |
The latest Rigel Pharmaceuticals stock forecast, released on Aug 17, 2022 by Piper Sandler company, set a price target of $2.00, which represents a 28.21% increase from the stock price at the time of the forecast ($1.56), and a -84.98% decrease from RIGL last price ($13.32).
Rigel Pharmaceuticals Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | - |
| Avg Price Target | - | - | - |
| Last Closing Price | $13.32 | $13.32 | $13.32 |
| Upside/Downside | -100.00% | -100.00% | -100.00% |
In the current month, the average price target of Rigel Pharmaceuticals stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Rigel Pharmaceuticals's last price of $13.32. This month's average price target is down NaN% compared to last quarter, and down NaN% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Sep 03, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Aug 07, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Dec 02, 2022 | Citigroup | - | Buy | Upgrade |
| Aug 18, 2022 | H.C. Wainwright | Buy | Buy | Hold |
| Aug 16, 2022 | Piper Sandler | Neutral | Neutral | Hold |
| Jun 09, 2022 | BMO Capital | Outperform | Outperform | Hold |
| Jun 08, 2022 | Jefferies | - | Buy | Downgrade |
| Jun 08, 2022 | H.C. Wainwright | Buy | Buy | Hold |
Rigel Pharmaceuticals's last stock rating was published by H.C. Wainwright on Sep 03, 2024. The company gave RIGL a "Buy" rating, the same as its previous rate.
Rigel Pharmaceuticals Financial Forecast
Rigel Pharmaceuticals Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Dec 18 | Sep 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | $28.13M | $26.89M | $26.07M | $51.28M | $22.41M | - | $16.73M | $20.41M | $21.54M | $26.27M | $81.02M | $18.45M | $18.39M | $16.02M | $55.76M | $15.40M | $20.86M | $10.41M | $12.62M | $37.86M | $4.87M |
| Avg Forecast | $50.90M | $49.40M | $46.55M | $43.25M | $47.70M | $41.94M | $33.42M | $31.47M | $34.10M | $27.20M | $25.70M | $24.07M | $36.52M | $22.61M | $23.65M | $17.58M | $21.90M | $23.56M | $20.37M | $30.85M | $18.37M | $17.24M | $13.75M | $56.71M | $15.66M | $11.96M | $9.28M | $11.72M | $37.86M | $5.21M |
| High Forecast | $55.84M | $54.20M | $51.07M | $47.45M | $52.33M | $44.77M | $36.66M | $34.53M | $37.41M | $29.84M | $28.20M | $26.41M | $40.07M | $24.80M | $23.65M | $18.42M | $22.94M | $24.69M | $21.34M | $32.32M | $19.25M | $18.06M | $14.41M | $59.42M | $16.40M | $12.53M | $9.72M | $12.28M | $45.43M | $6.25M |
| Low Forecast | $45.80M | $44.45M | $41.89M | $38.92M | $42.92M | $38.88M | $30.07M | $28.32M | $30.69M | $24.47M | $23.13M | $21.66M | $32.87M | $20.34M | $23.65M | $16.55M | $20.61M | $22.18M | $19.17M | $29.04M | $17.30M | $16.22M | $12.94M | $53.38M | $14.74M | $11.26M | $8.74M | $11.03M | $30.29M | $4.17M |
| # Analysts | 3 | 3 | 3 | 3 | 4 | 5 | 4 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | - | 1 | 2 | 2 | 2 | 3 | 3 | 3 | 3 | 3 | 2 | 3 | 4 | 5 | 7 | 16 |
| Surprise % | - | - | - | - | - | - | - | - | - | 1.03% | 1.05% | 1.08% | 1.40% | 0.99% | - | 0.95% | 0.93% | 0.91% | 1.29% | 2.63% | 1.00% | 1.07% | 1.17% | 0.98% | 0.98% | 1.74% | 1.12% | 1.08% | 1.00% | 0.93% |
Rigel Pharmaceuticals's average Quarter revenue forecast for Dec 23 based on 3 analysts is $34.10M, with a low forecast of $30.69M, and a high forecast of $37.41M. RIGL's average Quarter revenue forecast represents a 21.21% increase compared to the company's last Quarter revenue of $28.13M (Sep 23).
Rigel Pharmaceuticals EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Dec 18 | Sep 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 3 | 3 | 4 | 5 | 4 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | - | 1 | 2 | 2 | 2 | 3 | 3 | 3 | 3 | 3 | 2 | 3 | 4 | 5 | 7 | 16 |
| EBITDA | - | - | - | - | - | - | - | - | - | $-4.46M | $-5.27M | $-11.97M | $3.83M | $-17.97M | - | $-26.00M | $-21.00M | $-19.51M | $-12.77M | $41.99M | $-18.60M | $-13.58M | $-17.06M | $21.56M | $-16.69M | $-11.32M | $-20.43M | $-17.43M | $3.39M | $-23.61M |
| Avg Forecast | $-19.46M | $-18.89M | $-17.80M | $-16.54M | $-18.24M | $-16.03M | $-12.78M | $-26.97M | $-13.04M | $-10.40M | $-9.83M | $-24.52M | $-13.97M | $-19.74M | $-9.04M | $-22.29M | $-8.37M | $-15.61M | $-16.26M | $-11.80M | $-7.03M | $-18.11M | $-21.00M | $21.56M | $-12.52M | $-15.43M | $-23.35M | $-20.12M | $3.39M | $-25.18M |
| High Forecast | $-17.51M | $-17.00M | $-16.02M | $-14.88M | $-16.41M | $-14.87M | $-11.50M | $-21.58M | $-11.73M | $-9.36M | $-8.84M | $-19.61M | $-12.57M | $-15.80M | $-9.04M | $-17.83M | $-7.88M | $-12.49M | $-13.01M | $-11.10M | $-6.61M | $-14.49M | $-16.80M | $25.87M | $-10.02M | $-12.34M | $-18.68M | $-16.09M | $4.07M | $-20.14M |
| Low Forecast | $-21.35M | $-20.72M | $-19.53M | $-18.14M | $-20.01M | $-17.12M | $-14.02M | $-32.36M | $-14.30M | $-11.41M | $-10.78M | $-29.42M | $-15.32M | $-23.69M | $-9.04M | $-26.75M | $-8.77M | $-18.73M | $-19.51M | $-12.36M | $-7.36M | $-21.73M | $-25.19M | $17.24M | $-15.02M | $-18.52M | $-28.02M | $-24.14M | $2.71M | $-30.22M |
| Surprise % | - | - | - | - | - | - | - | - | - | 0.43% | 0.54% | 0.49% | -0.27% | 0.91% | - | 1.17% | 2.51% | 1.25% | 0.79% | -3.56% | 2.65% | 0.75% | 0.81% | 1.00% | 1.33% | 0.73% | 0.88% | 0.87% | 1.00% | 0.94% |
1 analysts predict RIGL's average Quarter EBITDA for Mar 23 to be $-24.52M, with a high of $-19.61M and a low of $-29.42M. This is -740.47% lower than Rigel Pharmaceuticals's previous annual EBITDA (Dec 22) of $3.83M.
Rigel Pharmaceuticals Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Dec 18 | Sep 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 3 | 3 | 4 | 5 | 4 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | - | 1 | 2 | 2 | 2 | 3 | 3 | 3 | 3 | 3 | 2 | 3 | 4 | 5 | 7 | 16 |
| Net Income | - | - | - | - | - | - | - | - | - | $-5.69M | $-6.60M | $-14.35M | $723.00K | $-19.67M | - | $-28.63M | $-22.64M | $-20.95M | $-13.82M | $39.50M | $-19.24M | $-14.17M | $-17.58M | $21.24M | $-17.20M | $-11.49M | $-20.61M | $-17.60M | $3.23M | $-23.77M |
| Avg Forecast | $1.40M | $2.11M | $2.46M | $1.32M | $3.28M | $1.03M | $-5.13M | $-28.46M | $-3.58M | $-12.46M | $-13.69M | $-25.88M | $-16.62M | $-21.20M | $-214.94M | $-23.52M | $-22.13M | $-16.76M | $-17.59M | $711.00M | $-19.53M | $-18.90M | $-21.63M | $21.24M | $-12.90M | $-15.67M | $-23.55M | $-20.31M | $3.23M | $-25.35M |
| High Forecast | $1.58M | $2.37M | $2.77M | $1.48M | $3.69M | $25.65M | $-4.46M | $-22.77M | $-1.19M | $-10.84M | $-11.91M | $-20.70M | $-14.45M | $-16.96M | $-214.94M | $-18.82M | $-20.44M | $-13.41M | $-14.07M | $853.20M | $-18.04M | $-15.12M | $-17.31M | $25.49M | $-10.32M | $-12.53M | $-18.84M | $-16.24M | $3.87M | $-20.28M |
| Low Forecast | $1.22M | $1.83M | $2.14M | $1.14M | $2.85M | $-21.55M | $-5.77M | $-34.16M | $-5.96M | $-14.03M | $-15.42M | $-31.05M | $-18.71M | $-25.44M | $-214.94M | $-28.23M | $-23.50M | $-20.11M | $-21.11M | $568.80M | $-20.75M | $-22.68M | $-25.96M | $16.99M | $-15.48M | $-18.80M | $-28.26M | $-24.37M | $2.58M | $-30.42M |
| Surprise % | - | - | - | - | - | - | - | - | - | 0.46% | 0.48% | 0.55% | -0.04% | 0.93% | - | 1.22% | 1.02% | 1.25% | 0.79% | 0.06% | 0.98% | 0.75% | 0.81% | 1.00% | 1.33% | 0.73% | 0.88% | 0.87% | 1.00% | 0.94% |
Rigel Pharmaceuticals's average Quarter net income forecast for Mar 23 is $-25.88M, with a range of $-31.05M to $-20.70M. RIGL's average Quarter net income forecast represents a -3679.08% decrease compared to the company's last Quarter net income of $723.00K (Dec 22).
Rigel Pharmaceuticals SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Dec 18 | Sep 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 3 | 3 | 4 | 5 | 4 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | - | 1 | 2 | 2 | 2 | 3 | 3 | 3 | 3 | 3 | 2 | 3 | 4 | 5 | 7 | 16 |
| SG&A | - | - | - | - | - | - | - | - | - | $24.86M | $26.31M | $27.73M | $32.17M | $25.90M | - | $27.40M | $24.52M | $22.88M | $22.38M | $22.12M | $21.82M | $17.43M | $18.92M | $18.43M | $18.31M | $18.12M | $18.21M | $19.95M | $21.37M | $18.07M |
| Avg Forecast | $44.98M | $43.66M | $41.14M | $38.22M | $42.16M | $37.06M | $29.53M | $28.42M | $30.14M | $24.04M | $22.72M | $21.27M | $32.28M | $19.98M | $20.91M | $15.53M | $19.35M | $18.30M | $18.00M | $27.27M | $16.24M | $15.23M | $12.15M | $18.43M | $13.73M | $10.57M | $8.20M | $10.36M | $21.37M | $4.61M |
| High Forecast | $49.35M | $47.90M | $45.13M | $41.93M | $46.25M | $39.57M | $32.40M | $34.10M | $33.06M | $26.37M | $24.92M | $23.34M | $35.41M | $21.92M | $20.91M | $16.28M | $20.28M | $21.96M | $18.86M | $28.57M | $17.01M | $15.96M | $12.73M | $22.12M | $16.48M | $11.07M | $8.59M | $10.85M | $25.64M | $5.53M |
| Low Forecast | $40.48M | $39.29M | $37.02M | $34.39M | $37.93M | $34.37M | $26.58M | $22.73M | $27.12M | $21.63M | $20.44M | $19.14M | $29.05M | $17.98M | $20.91M | $14.62M | $18.22M | $14.64M | $16.95M | $25.67M | $15.29M | $14.34M | $11.44M | $14.74M | $10.99M | $9.95M | $7.72M | $9.75M | $17.10M | $3.69M |
| Surprise % | - | - | - | - | - | - | - | - | - | 1.03% | 1.16% | 1.30% | 1.00% | 1.30% | - | 1.76% | 1.27% | 1.25% | 1.24% | 0.81% | 1.34% | 1.14% | 1.56% | 1.00% | 1.33% | 1.71% | 2.22% | 1.93% | 1.00% | 3.92% |
Rigel Pharmaceuticals's average Quarter SG&A projection for Dec 23 is $30.14M, based on 3 Wall Street analysts, with a range of $27.12M to $33.06M. The forecast indicates a 21.25% rise compared to RIGL last annual SG&A of $24.86M (Sep 23).
Rigel Pharmaceuticals EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Dec 18 | Sep 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 3 | 3 | 4 | 5 | 4 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | - | 1 | 2 | 2 | 2 | 3 | 3 | 3 | 3 | 3 | 2 | 3 | 4 | 5 | 7 | 16 |
| EPS | - | - | - | - | - | - | - | - | - | $-0.03 | $-0.04 | $-0.08 | - | $-0.11 | - | $-0.17 | $-0.13 | $-0.12 | $-0.08 | $0.23 | $-0.11 | $-0.08 | $-0.10 | $0.13 | $-0.10 | $-0.07 | $-0.12 | $-0.11 | $0.02 | $-0.14 |
| Avg Forecast | $0.08 | $0.12 | $0.14 | $0.07 | $0.19 | $0.06 | $-0.29 | $-0.29 | $-0.20 | $-0.71 | $-0.78 | $-0.96 | $-0.95 | $-1.32 | $-1.23 | $-0.14 | $-0.13 | $-0.10 | $-0.11 | - | $-0.11 | $-0.12 | $-0.13 | $0.13 | $-0.08 | $-0.11 | $-0.14 | $-0.13 | $0.03 | $-0.16 |
| High Forecast | $0.09 | $0.14 | $0.16 | $0.08 | $0.21 | $1.46 | $-0.25 | $-0.25 | $-0.07 | $-0.62 | $-0.68 | $-0.83 | $-0.82 | $-1.15 | $-1.23 | $-0.13 | $-0.12 | $-0.09 | $-0.10 | $0.01 | $-0.10 | $-0.11 | $-0.12 | $0.14 | $-0.07 | $-0.10 | $-0.13 | $-0.12 | $0.04 | $-0.13 |
| Low Forecast | $0.07 | $0.10 | $0.12 | $0.07 | $0.16 | $-1.23 | $-0.33 | $-0.32 | $-0.34 | $-0.80 | $-0.88 | $-1.08 | $-1.07 | $-1.49 | $-1.23 | $-0.15 | $-0.13 | $-0.11 | $-0.12 | - | $-0.12 | $-0.13 | $-0.14 | $0.12 | $-0.09 | $-0.12 | $-0.15 | $-0.14 | $0.02 | $-0.19 |
| Surprise % | - | - | - | - | - | - | - | - | - | 0.05% | 0.05% | 0.09% | -0.00% | 0.08% | - | 1.24% | 1.03% | 1.20% | 0.73% | 47.09% | 0.98% | 0.66% | 0.75% | 0.99% | 1.23% | 0.64% | 0.87% | 0.86% | 0.67% | 0.88% |
According to 1 Wall Street analysts, Rigel Pharmaceuticals's projected average Quarter EPS for Mar 23 is $-0.96, with a low estimate of $-1.08 and a high estimate of $-0.83. This represents a -22905.71% decrease compared to RIGL previous annual EPS of - (Dec 22).
Rigel Pharmaceuticals Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| EFTR | eFFECTOR Therapeutics | $0.04 | $5.50 | 13650.00% | Buy |
| ELEV | Elevation Oncology | $0.63 | $9.00 | 1328.57% | Buy |
| RVPH | Reviva Pharmaceuticals | $1.35 | $10.00 | 640.74% | Buy |
| XFOR | X4 Pharmaceuticals | $0.65 | $3.67 | 464.62% | Buy |
| IMMX | Immix Biopharma | $1.97 | $7.00 | 255.33% | Buy |
| ABOS | Acumen Pharmaceuticals | $2.22 | $7.00 | 215.32% | Buy |
| INZY | Inozyme Pharma | $4.98 | $14.00 | 181.12% | Buy |
| DAWN | Day One Biopharmaceuticals | $14.20 | $38.80 | 173.24% | Buy |
| CDTX | Cidara Therapeutics | $11.44 | $24.00 | 109.79% | Buy |
| LPTX | Leap Therapeutics | $2.81 | $5.50 | 95.73% | Buy |
| TERN | Terns Pharmaceuticals | $7.81 | $12.50 | 60.05% | Buy |
| MREO | Mereo BioPharma Group | $4.32 | $6.75 | 56.25% | Buy |
| ZURA | Zura Bio | $3.62 | $5.00 | 38.12% | Buy |
| VECT | VectivBio | $16.87 | $18.00 | 6.70% | Buy |
| NBRV | Nabriva Therapeutics | $1.42 | $1.00 | -29.58% | - |
| RIGL | Rigel Pharmaceuticals | $13.32 | $1.50 | -88.74% | Buy |
RIGL Forecast FAQ
Is Rigel Pharmaceuticals a good buy?
Yes, according to 5 Wall Street analysts, Rigel Pharmaceuticals (RIGL) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 4 'Buy' recommendations, accounting for 80.00% of RIGL's total ratings.
What is RIGL's price target?
Rigel Pharmaceuticals (RIGL) average price target is $1.5 with a range of $1 to $2, implying a -88.74% from its last price of $13.32. The data is based on 5 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Rigel Pharmaceuticals stock go up soon?
According to Wall Street analysts' prediction for RIGL stock, the company can go down by -88.74% (from the last price of $13.32 to the average price target of $1.5), down by -84.98% based on the highest stock price target, and down by -92.49% based on the lowest stock price target.
Can Rigel Pharmaceuticals stock reach $20?
RIGL's average twelve months analyst stock price target of $1.5 does not support the claim that Rigel Pharmaceuticals can reach $20 in the near future.
What are Rigel Pharmaceuticals's analysts' financial forecasts?
Rigel Pharmaceuticals's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $154.53M (high $168.29M, low $140.2M), average EBITDA is $-74.02M (high $-64.353M, low $-83.508M), average net income is $-29.288M (high $2.11M, low $-58.631M), average SG&A $137.17M (high $152.32M, low $121.61M), and average EPS is $-0.335 (high $1.17, low $-1.719). RIGL's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $190.1M (high $208.55M, low $171.06M), average EBITDA is $-72.687M (high $-65.406M, low $-79.742M), average net income is $7.28M (high $8.2M, low $6.33M), average SG&A $168.01M (high $184.31M, low $151.18M), and average EPS is $0.415 (high $0.467, low $0.361).
Did the RIGL's actual financial results beat the analysts' financial forecasts?
Based on Rigel Pharmaceuticals's last annual report (Dec 2023), the company's revenue was $116.88M, beating the average analysts forecast of $111.08M by 5.22%. Apple's EBITDA was $-20.491M, missing the average prediction of $-57.785M by -64.54%. The company's net income was $-25.091M, missing the average estimation of $-55.603M by -54.88%. Apple's SG&A was $105.74M, beating the average forecast of $98.17M by 7.71%. Lastly, the company's EPS was $-0.14, missing the average prediction of $-2.652 by -94.72%. In terms of the last quarterly report (Sep 2023), Rigel Pharmaceuticals's revenue was $28.13M, beating the average analysts' forecast of $27.2M by 3.44%. The company's EBITDA was $-4.465M, missing the average prediction of $-10.4M by -57.07%. Rigel Pharmaceuticals's net income was $-5.692M, missing the average estimation of $-12.458M by -54.31%. The company's SG&A was $24.86M, beating the average forecast of $24.04M by 3.40%. Lastly, the company's EPS was $-0.0326, missing the average prediction of $-0.71 by -95.41%